CLINICAL TRIALS PROFILE FOR XENICAL

All Clinical Trials for XENICAL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001723 ↗	Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2	1998-05-01	Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and other disorders of the heart and lungs. Individuals with the onset of obesity during childhood or adolescence are at an increased risk of obesity-related, diseases, both during adolescence and later in adult life. African American girls and women are at an increased risk for obesity, and have substantial rates of obesity-related diseases and causes of death. Further, many African American adult women fail to respond to many of the therapeutic approaches used to treat obesity. At present there are no medical therapies proven effective for the correction of severe obesity in children or adolescents. One medication that may have a favorable risk-benefit ratio in pediatric populations is Orlistat (Xenical, Hoffmann LaRoche). Orlistat works by preventing the action of enzymes in the digestive process, interfering with the absorption of approximately 1/3 of the fat eaten in the diet. Xenical appears to be effective for reducing weight and obesity-associated diseases in obese adults. Researchers propose to determine the safety, tolerability, and efficacy of Xenical in 12-17 year old severely obese African American and Caucasian children and adolescents who have one or more obesity-related disease (hypertension, hyperlipidemia, sleep apnea, hepatic steatosis, insulin resistance, impaired glucose tolerance, or Type 2 diabetes).
NCT00001723 ↗	Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases	Completed	Roche Pharma AG	Phase 2	1998-05-01	Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and other disorders of the heart and lungs. Individuals with the onset of obesity during childhood or adolescence are at an increased risk of obesity-related, diseases, both during adolescence and later in adult life. African American girls and women are at an increased risk for obesity, and have substantial rates of obesity-related diseases and causes of death. Further, many African American adult women fail to respond to many of the therapeutic approaches used to treat obesity. At present there are no medical therapies proven effective for the correction of severe obesity in children or adolescents. One medication that may have a favorable risk-benefit ratio in pediatric populations is Orlistat (Xenical, Hoffmann LaRoche). Orlistat works by preventing the action of enzymes in the digestive process, interfering with the absorption of approximately 1/3 of the fat eaten in the diet. Xenical appears to be effective for reducing weight and obesity-associated diseases in obese adults. Researchers propose to determine the safety, tolerability, and efficacy of Xenical in 12-17 year old severely obese African American and Caucasian children and adolescents who have one or more obesity-related disease (hypertension, hyperlipidemia, sleep apnea, hepatic steatosis, insulin resistance, impaired glucose tolerance, or Type 2 diabetes).
NCT00001723 ↗	Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases	Completed	Jack Yanovski	Phase 2	1998-05-01	Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and other disorders of the heart and lungs. Individuals with the onset of obesity during childhood or adolescence are at an increased risk of obesity-related, diseases, both during adolescence and later in adult life. African American girls and women are at an increased risk for obesity, and have substantial rates of obesity-related diseases and causes of death. Further, many African American adult women fail to respond to many of the therapeutic approaches used to treat obesity. At present there are no medical therapies proven effective for the correction of severe obesity in children or adolescents. One medication that may have a favorable risk-benefit ratio in pediatric populations is Orlistat (Xenical, Hoffmann LaRoche). Orlistat works by preventing the action of enzymes in the digestive process, interfering with the absorption of approximately 1/3 of the fat eaten in the diet. Xenical appears to be effective for reducing weight and obesity-associated diseases in obese adults. Researchers propose to determine the safety, tolerability, and efficacy of Xenical in 12-17 year old severely obese African American and Caucasian children and adolescents who have one or more obesity-related disease (hypertension, hyperlipidemia, sleep apnea, hepatic steatosis, insulin resistance, impaired glucose tolerance, or Type 2 diabetes).
NCT00108524 ↗	A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss	Completed	US Department of Veterans Affairs	N/A	2004-07-01	This study compares two types of diet interventions: a low carbohydrate ketogenic diet (Atkins) and a low-fat diet combined with a medication (Orlistat).
NCT00108524 ↗	A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss	Completed	VA Office of Research and Development	N/A	2004-07-01	This study compares two types of diet interventions: a low carbohydrate ketogenic diet (Atkins) and a low-fat diet combined with a medication (Orlistat).
NCT00152360 ↗	The Effect of Xenical on Weight and Risk Factors	Completed	University of British Columbia	Phase 4	2005-06-01	The purpose of this study is to determine the effect of using the weight loss medication Xenical (generic name - orlistat) on weight loss and change in heart disease risk factors in patients of the Healthy Heart Program Lipid Clinic at St. Paul's Hospital over a three month period. Xenical works by blocking the body's absorption of dietary fat in the gut, allowing it to pass through to be excreted, therefore reducing the intake of fat and calories. This is a pilot study supported by Hoffmann-La Roche Limited which produces Xenical. The aim is to investigate whether weight loss will also result in reductions in heart disease risk factors that may allow for less of a need for medications controlling lipid levels, hypertension and plasma glucose.

Clinical Trial Conditions for XENICAL

Condition Name

Condition Name for XENICAL
Intervention	Trials
Obesity	16
Hepatitis C	2
Diabetes Mellitus	2
Fatty Liver	2

Condition MeSH

Condition MeSH for XENICAL
Intervention	Trials
Obesity	12
Weight Loss	5
Overweight	5
Diabetes Mellitus	3

Clinical Trial Locations for XENICAL

Trials by Country

Trials by Country for XENICAL
Location	Trials
United States	26
Iran, Islamic Republic of	1
Singapore	1
Spain	1
Russian Federation	1

Trials by US State

Trials by US State for XENICAL
Location	Trials
Texas	3
North Carolina	2
Ohio	2
Connecticut	2
Missouri	2

Clinical Trial Progress for XENICAL

Clinical Trial Phase

Clinical Trial Phase for XENICAL
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	10
Phase 3	1

Clinical Trial Status

Clinical Trial Status for XENICAL
Clinical Trial Phase	Trials
Completed	14
Active, not recruiting	2
Unknown status	2

Clinical Trial Sponsors for XENICAL

Sponsor Name

Sponsor Name for XENICAL
Sponsor	Trials
Hoffmann-La Roche	4
Pennington Biomedical Research Center	1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1

Sponsor Type

Sponsor Type for XENICAL
Sponsor	Trials
Other	17
Industry	11
U.S. Fed	3

Xenical (orlistat): Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is Xenical and what is its clinical status?

Xenical is the branded prescription form of orlistat (pancreatic and gastric lipase inhibitor) for weight management. Market supply today is primarily supported by established commercial manufacturing and ongoing post-launch activities rather than large new pivotal programs.

A clinical-trials “update” for Xenical is constrained by the drug’s age and the regulatory reality for off-patent products: most newer studies that remain active or recently reported tend to be comparative, formulation/bioequivalence, special populations, or real-world evidence rather than new Phase 3 superiority trials.

Trial activity pattern (observed in major registries)

Across public trial registries, orlistat studies cluster around:

• Obesity management outcomes (weight loss, % weight loss, BMI change).
• Special populations (adolescents or comorbidities) where permitted.
• Comparative designs (orlistat vs. behavioral interventions, or orlistat vs. other anti-obesity strategies).
• Safety and tolerability follow-up after long-term use.

The practical implication for investors: Xenical’s clinical pipeline is not the dominant driver of market growth. Commercial performance hinges more on access (coverage, pharmacy uptake), competitive positioning versus GLP-1 and related agents, and OTC substitution dynamics for orlistat in jurisdictions where the dose/salt is available without prescription.

What clinical outcomes and safety endpoints dominate for orlistat?

Across published and registry-level evidence for orlistat class use, the endpoints that typically matter for regulators and payers are:

• Weight loss efficacy: change in body weight, BMI, and proportion achieving clinically meaningful weight loss (often defined as ≥5% or higher over a set timeframe).
• Maintenance: durability of weight loss versus relapse.
• Gastrointestinal adverse events: the main on-target safety signal (oily stools, fecal urgency/incontinence, flatulence, abdominal discomfort).
• Adherence and discontinuation: tolerability drives persistence.
• Nutritional safety: fat-soluble vitamin reductions and the need for supplementation programs in product labeling and clinical practice.

For business decision-making, the payer-relevant effect size is usually evaluated against two constraints: 1) orlistat’s efficacy is modest relative to injectable incretin-based therapies, and
2) tolerability impacts continuation, which affects real-world outcomes.

Are there meaningful recent Xenical-specific late-stage readouts?

No Xenical-specific, late-stage pivot appears to be driving the current market narrative. Public trial activity for orlistat remains present but typically does not look like a new Phase 3 program that would reset competitive positioning.

That means the clinical-trials “update” for Xenical is best treated as incremental evidence (safety, real-world outcomes, comparative effectiveness) rather than a catalyst for a step-change in brand demand.

---

How big is the Xenical/orlistat market and what drives demand?

What is the market structure around Xenical?

Xenical competes within a broader obesity and weight-management ecosystem:

• Direct orlistat competition: other orlistat-branded and generic products, including different salt forms and dose formats.
• Therapeutic substitution: incretin-based injectables and newer oral anti-obesity agents.
• Behavioral and device-based weight loss: diet programs, digital therapeutics, and bariatric surgery referrals (where covered).

Because orlistat is widely available in many markets as generic or OTC depending on jurisdiction, brand-level pricing power is constrained. Xenical’s differentiator is historical brand presence plus clinician familiarity in prescription settings.

What are the demand drivers for Xenical in 2026?

Key demand factors remain structural:

• Reimbursement and formulary access: coverage rules and prior authorization thresholds determine volume more than new efficacy.
• Patient out-of-pocket cost: orlistat often wins on cost compared with premium anti-obesity therapies.
• Safety tolerability trade-off: gastrointestinal side effects limit uptake versus more tolerable oral or injectable options for some segments.
• Adherence environment: fat-restricted diet guidance and vitamin supplementation routines influence persistence.
• Competitive substitution: as GLP-1 penetration expands, orlistat demand shifts to lower-acuity or cost-sensitive cohorts.

Where the competitive pressure is highest

Competition is strongest in:

• Commercially insured populations where incretin access is available.
• Patients already eligible for anti-obesity drugs with sufficient formulary coverage.
• Clinics running high-throughput obesity pathways that steer to newer classes.

Where orlistat persists is typically in:

• Lower-cost-access settings and regions with limited coverage for newer agents.
• Patients who do not tolerate incretin-based therapy or do not want injectable regimens.
• Step therapy environments where cheaper oral agents are tried first.

---

How should investors project Xenical performance and market trajectory?

Projection framework (what matters most)

A practical projection for Xenical is driven by three forces: 1) Share shift from older oral anti-obesity agents to incretins
2) Orlistat volume stability where cost access maintains demand
3) Price pressure from generic competition and formulary cycling

Because Xenical has no dominant late-stage catalyst, projection assumptions should treat clinical activity as supporting background rather than a demand lever.

Base-case outlook

A base-case view for Xenical is:

• Revenue: low-growth or mild decline driven by continued share loss to incretin-based therapies, partially offset by persistent use in cost-sensitive segments.
• Volume: stable to down modestly depending on country-specific reimbursement and OTC dynamics.
• Margins: pressured by generic and multi-brand orlistat competition, with brand protection limited to managed markets.

Downside scenario

Downside conditions:

• broader formulary restriction for orlistat,
• accelerated price compression,
• higher conversion to incretin regimens as access expands.

This yields:

• more pronounced revenue decline,
• higher promotional spend to defend share,
• increased risk of brand erosion in key geographies.

Upside scenario

Upside conditions:

• sustained or improved reimbursement for older anti-obesity orals in cost-controlled systems,
• favorable persistence in real-world cohorts,
• stable OTC boundaries that keep prescription demand intact.

Upside yields:

• revenue stability or slight growth,
• moderated share loss versus base case.

---

What patent and exclusivity realities shape Xenical’s business?

Xenical (orlistat) is a mature product with limited ability to block generic entry through active patent families in many markets. Business protection today is mainly:

• Brand and formulation differentiation where applicable
• Market access and payer contracting
• Manufacturing quality and supply continuity

This shifts strategic value away from “patent-driven growth” and toward commercial execution and portfolio management across obesity therapeutics.

---

Market positioning: how to benchmark Xenical against the obesity drug landscape

Competitive benchmark logic

For decision-making, investors can benchmark orlistat against:

• Efficacy ceiling: modest average weight loss relative to incretins
• Tolerability profile: GI adverse events drive discontinuation risk
• Cost advantage: can be lower than premium anti-obesity therapies
• Route preference: oral regimen can beat injectable aversion, but tolerability still matters

Payer lens

Payers typically prefer:

• predictable safety and low cost,
• measurable endpoints for approval renewal,
• clear step-therapy rationale.

Xenical’s value proposition is strongest when payer policy favors low-cost oral options and when required continuation rules align with early weight-loss thresholds.

---

Key Takeaways

• Xenical’s clinical activity is best characterized as incremental (safety, real-world outcomes, comparative studies), not as a new late-stage catalyst.
• Market growth is constrained by generics and OTC dynamics and by continued therapeutic substitution to incretin-based obesity therapies.
• Projections should prioritize reimbursement, access, and price compression over clinical readouts.
• Base case: revenue low-growth to mild decline with stability in cost-sensitive cohorts; downside accelerates with formulary restriction and share shift; upside depends on managed access that preserves older oral uptake.

---

FAQs

1) What is Xenical’s mechanism of action?

Xenical (orlistat) inhibits gastrointestinal lipases, reducing dietary fat absorption.

2) What safety endpoints matter most for long-term orlistat use?

Gastrointestinal adverse events and nutritional considerations (fat-soluble vitamin reductions) drive labeling-focused monitoring and supplementation practices.

3) Is Xenical currently supported by new Phase 3 efficacy catalysts?

Publicly visible late-stage repositioning catalysts are not the dominant driver of Xenical’s current market narrative; trial activity is generally incremental.

4) Why does Xenical face pressure despite having an established safety profile?

Therapeutic substitution to incretin-based anti-obesity drugs reduces share, especially where payer access is broad.

5) What is the most important variable for Xenical revenue projection?

Managed access: formulary inclusion, prior authorization rules, and step-therapy policies that govern cost-sensitive patient routing.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. Xenical (orlistat) and orlistat-related clinical trials registry entries. (Accessed 2026-04-28).
[2] European Medicines Agency. Product information and assessment documents for orlistat-containing medicinal products (Xenical and related formulations) as published in EMA records. (Accessed 2026-04-28).
[3] U.S. FDA. Approved drug labeling and prescribing information references for orlistat (Xenical). (Accessed 2026-04-28).